This was translated into clinical practice in a phase I trial of 60 patients with HER2 expressing non-breast/GI or HER2 mutant solid tumors with an ORR of 28.3%, but, surprisingly, ORR was 72.7%, and median PFS was 11.3 [95% CI, 8.1–14.3] months in the HER2 mutant NSCLC patients [62]. Here, ERBB2 is linked to non-small cell lung carcinoma.